Orion Corporation (pharmaceutical company): Difference between revisions
Appearance
Content deleted Content added
Line 31: | Line 31: | ||
| |
| |
||
*[[Management of Parkinson's disease|Antiparkinson agents]] |
*[[Management of Parkinson's disease|Antiparkinson agents]] |
||
:* Comtan (''[[entacapone]]'') |
:* Comtan/Comtess (''[[entacapone]]'') |
||
:* Stalevo (''[[entacapone]], [[carbidopa]], [[ |
:* Stalevo (''[[entacapone]], [[carbidopa]], [[levodopa]]'') |
||
* [[Analgesic]]s |
* [[Analgesic]]s |
Revision as of 08:43, 4 May 2020
Native name | Orion Oyj |
---|---|
Company type | Julkinen osakeyhtiö |
Nasdaq Helsinki: ORNAV,ORNBV | |
Industry | Pharmaceutical industry |
Founded | 1917 |
Headquarters | Espoo, Finland |
Key people | Timo Lappalainen (President and CEO), Hannu Syrjänen (Chairman) |
Products | Pharmaceuticals, active pharmaceutical ingredients and diagnostic tests |
Revenue | €1.074 billion (2016) |
€315 million (2016) | |
€249 million (2016) | |
Total assets | €1.063 billion (2016) |
Total equity | €641 million (2016) |
Number of employees | 3,446 (2016) |
Website | www |
Footnotes / references [1] |
Orion Corporation (Finnish: Orion Oyj),[2][3] founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.
Orion's class A and B shares are listed on the Helsinki Stock Exchange.
Products
|
References
- ^ https://www.orion.fi/globalassets/documents/orion-group/investors/annual-reports/orion-financial-statement-documents-2016.pdf
- ^ "Orion Oyj". Business Information System. Finnish Patent and Registration Office and Finnish Tax Administration. Retrieved 22 October 2019.
- ^ "Yhtiöjärjestys" [Corporate by-laws] (in Finnish). Espoo: Orion Oyj. 22 March 2017. Retrieved 22 October 2019.
External links